Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;100(2):350-353.
doi: 10.1002/ajh.27550. Epub 2024 Dec 12.

Efficacy and Safety of Obinutuzumab in Immune-Mediated Thrombotic Thrombocytopenic Purpura

Julia Weisinger  1 , Raïda Bouzid  1   2 , Jehane Fadlallah  3 , Christelle Barbet  4 , Francois Provot  5 , Pascale Poullin  6 , Antoine Neel  7 , Manon Marie  8 , Virginie Rieu  9 , Tarik Kanouni  10 , Olivier Moranne  11 , Elie Azoulay  12 , Zora Marjanovic  1 , Elise Corre  1 , Anne-Christine Joly  13 , Minh-Tam Baylatry  13 , Bérangère S Joly  1   2   14 , Agnes Veyradier  1   2   14 , Paul Coppo  1   2 ; French National Center for Thrombotic Microangiopathies (CNR‐MAT)
Collaborators, Affiliations

Efficacy and Safety of Obinutuzumab in Immune-Mediated Thrombotic Thrombocytopenic Purpura

Julia Weisinger et al. Am J Hematol. 2025 Feb.
No abstract available

Keywords: ADAMTS13; obinutuzumab; prognosis; relapse; thrombotic thrombocytopenic purpura.

PubMed Disclaimer

Conflict of interest statement

J. Weisinger, R. Bouzid do not have any conflicts of interest to declare. P. Coppo is member of the Clinical Advisory Board for Alexion, Sanofi and Takeda. A. Veyradier is a member of the French clinical advisory board for Sanofi and Takeda. B. Joly has participated to Advisory boards for Sanofi, Takeda and Alexion. The other authors have no conflicts of interest to declare.

References

    1. Joly B. S., Coppo P., and Veyradier A., “Thrombotic Thrombocytopenic Purpura,” Blood 129, no. 21 (2017): 2836–2846. - PubMed
    1. Coppo P., Bubenheim M., Azoulay E., et al., “A Regimen With Caplacizumab, Immunosuppression, and Plasma Exchange Prevents Unfavorable Outcomes in Immune‐Mediated TTP,” Blood 137, no. 6 (2021): 733–742. - PMC - PubMed
    1. Zheng X. L., Vesely S. K., Cataland S. R., et al., “ISTH Guidelines for Treatment of Thrombotic Thrombocytopenic Purpura,” Journal of Thrombosis and Haemostasis 18, no. 10 (2020): 2496–2502. - PMC - PubMed
    1. Cuker A., Cataland S. R., Coppo P., et al., “Redefining Outcomes in Immune TTP: An International Working Group Consensus Report,” Blood 137, no. 14 (2021): 1855–1861. - PubMed
    1. Hie M., Gay J., Galicier L., et al., “Preemptive Rituximab Infusions After Remission Efficiently Prevent Relapses in Acquired Thrombotic Thrombocytopenic Purpura,” Blood 124, no. 2 (2014): 204–210. - PubMed

LinkOut - more resources